Bydureon Tracker App
Track Exenatide Extended-Release Weekly Doses and HbA1c in Shotlee
Bydureon (exenatide extended-release 2 mg) is a once-weekly GLP-1 receptor agonist for type 2 diabetes, FDA approved in January 2012. It uses a unique microsphere depot formulation that releases exenatide slowly over 7 days — a single fixed dose with no escalation required. The Bydureon BCise autoinjector (approved 2017) eliminated manual reconstitution. DURATION-1 demonstrated -1.6% HbA1c at 30 weeks.
25,000+
GLP-1 Users Tracking
4.8★
App Rating
Free
Always Free
What Is Bydureon (Exenatide Extended-Release)?
Bydureon is the extended-release formulation of exenatide — the first GLP-1 receptor agonist ever approved (the twice-daily version, Byetta, launched in 2005). Bydureon uses PLGA microspheres (poly-lactic-co-glycolic acid) to encapsulate exenatide and release it over 7 days after a single subcutaneous injection. This depot technology converts a twice-daily peptide into a once-weekly medication.
A single fixed dose of 2 mg per week is used for all patients — there is no titration schedule. The Bydureon BCise pen (approved 2017) further simplified administration by pre-mixing the microsphere suspension, eliminating the multi-step manual reconstitution required by the original Bydureon vial. While less potent than newer agents like semaglutide or tirzepatide, Bydureon remains an established option with a long safety record and a fixed, simple weekly dosing structure.
No Dose Escalation Required
Bydureon uses a single 2 mg weekly dose for all patients — there is no titration schedule. This simplifies tracking but also means the microsphere injection technique must be performed correctly every week for consistent drug release.
DURATION-1 Clinical Results (30 Weeks)
HbA1c reduction (DURATION-1)
-1.6%
Mean HbA1c reduction with exenatide ER 2 mg at 30 weeks vs twice-daily exenatide in DURATION-1.
Body weight change
-3.7 kg
Mean weight reduction with exenatide ER vs -3.6 kg with twice-daily exenatide at 30 weeks in DURATION-1.
HbA1c target achieved
77.4%
Proportion of exenatide ER patients achieving HbA1c less than 7.0% at 30 weeks vs 61.4% with twice-daily exenatide.
How to Inject Bydureon BCise Correctly
Remove the Bydureon BCise pen from the refrigerator 15 minutes before injection — injecting cold microsphere suspension causes injection site discomfort and inconsistent release
Shake the pen vigorously for at least 15 seconds until the white microspheres are uniformly suspended — incomplete mixing causes dose variability
Select your injection site (abdomen, thigh, or upper arm), pinch the skin, insert the needle fully, and inject slowly — the thick microsphere suspension requires firm steady pressure
Log the injection in Shotlee immediately: date, dose, site, any site reactions (nodules at injection site are common and expected with microsphere formulations), and any GI symptoms
What to Track in Shotlee
Fixed weekly dosing means consistency in technique matters most — track every injection and outcome metric in Shotlee.
Weekly Injection Logs
Record injection date, site, and technique notes. Consistent site rotation minimises nodule accumulation at microsphere injection sites.
HbA1c & Fasting Glucose
Enter lab HbA1c at each clinic visit. With a fixed dose, HbA1c response directly reflects your personal pharmacodynamics.
Weekly Weight
Track body weight weekly. Exenatide ER shows modest but consistent weight reduction — quantify your personal response.
Injection Site Reactions
Subcutaneous nodules are common with microsphere injections and usually resolve within 4–8 weeks. Log size and location over time.
GI Side Effects
Nausea is less severe with the extended-release formulation than with twice-daily Byetta. Log any GI symptoms to track severity over time.
CV Risk Markers
EXSCEL showed CV non-inferiority. Track blood pressure and lipids alongside HbA1c for a complete metabolic picture.
Protocol FAQs
Both contain exenatide, but Byetta is twice-daily injection (5 or 10 mcg) and Bydureon is once-weekly extended-release (2 mg). Bydureon provides more consistent drug levels, less nausea, and comparable or slightly better HbA1c reduction. DURATION-1 showed Bydureon reduced HbA1c by 1.6% vs twice-daily exenatide.
Small firm bumps at the injection site are common with Bydureon due to the PLGA microspheres. They are typically not painful and resolve within 4–8 weeks. Rotating injection sites every week reduces nodule accumulation. Log injection sites in Shotlee to maintain proper rotation.
The EXSCEL trial showed non-inferiority but not superiority for MACE vs placebo in T2D patients. Unlike semaglutide (SUSTAIN-6, SELECT) and liraglutide (LEADER), Bydureon has not demonstrated CV superiority. It is considered CV-safe but not specifically cardioprotective.
Bydureon remains prescribed, particularly where cost or formulary access is a factor. It has a long safety record since 2012 and the BCise autoinjector is well-tolerated. However, semaglutide and tirzepatide deliver meaningfully greater HbA1c and weight reduction for patients who can access them.
Exenatide ER released from microspheres takes 6–7 weeks to reach steady-state plasma concentrations. Initial HbA1c response may be modest and should be assessed at 3 months when steady state is established. Track your HbA1c at each clinic visit in Shotlee.
References
- [1]Clinical TrialDrucker DJ, et al. "Exenatide once weekly versus twice daily for the treatment of type 2 diabetes (DURATION-1)." Lancet. 2008;372(9645):1240-1250.
- [2]Clinical TrialHolman RR, et al. "Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL)." NEJM. 2017;377(13):1228-1239.
Track Your Bydureon Protocol in Shotlee
Log weekly injections, injection site reactions, HbA1c, and weight progress — free in Shotlee.
🚀 Use Shotlee for Free